Question · asked by 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control: Death or dependence (mRS 4 to 6) at day 90

Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in death or dependence (mRS 4–6) compared with placebo/open control (low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control
Death or dependence (mRS 4–6) · adults with acute spontaneous intracerebral haemorrhage
Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in death or dependence (mRS 4–6) compared with placebo/open control (low certainty).
Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane Headline outcomes only
RR 0.88 [0.74, 1.05]7 studies · 1454 participantsLow

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage
2023 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.